Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD(TM), PrecisionCHD(TM) and the HeartRisk(TM) population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes.
Cardiovascular disease remains a significant burden on employer-sponsored health plans, contributing to rising premiums and lost productivity. According to the American Heart Association, heart disease and stroke account for approximately $351 billion in annual healthcare costs and lost productivity in the United States alone. By leveraging artificial intelligence and genetic-epigenetic technology, Cardio Diagnostics aims to shift the paradigm from reactive treatment to proactive prevention, enabling earlier intervention for at-risk populations.
The company’s Epi+Gen CHD test combines genetic and epigenetic markers to assess an individual’s risk for coronary heart disease, while PrecisionCHD offers a more comprehensive analysis for personalized prevention strategies. The HeartRisk platform provides population-level insights, allowing employers and plan sponsors to identify high-risk groups and implement targeted wellness programs. These tools are designed to integrate seamlessly into existing benefits frameworks, offering actionable data without requiring invasive procedures.
Participation in these conferences underscores Cardio Diagnostics’ commitment to expanding its reach within the employer benefits market. The events attract key decision-makers from large corporations, union trusts, and benefits consulting firms, providing a platform to demonstrate the value of precision medicine in managing chronic disease. By engaging directly with benefits professionals, the company hopes to drive adoption of its technologies and ultimately reduce the economic impact of cardiovascular disease.
For more information about Cardio Diagnostics and its products, visit the company’s newsroom at https://ibn.fm/CDIO. The full press release can be accessed at https://ibn.fm/qFRHu.
